Sevelamer hydrochloride

PreclinicalSmall molecule

Sevelamer hydrochloride is one of 6 small molecule programs targeting End-Stage Renal Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

End-Stage Renal DiseaseCompleted

End-Stage Renal DiseasePreclinical

Completed

Competition

Competitive Landscape

7 competitors in End-Stage Renal Disease

#DrugCompanyPhaseTrials

Prograf

VVeloxis Pharmaceuticals

Approved

2 2

Wellbutrin

GSK

Preclinical

1 3

Apabetalone

RResverlogix Corp

Phase 2

1 4

Ribupatide

KKailera

Phase 1

1 5

Equine Anti-Thymocyte Globulin

NNational Cancer Institute (NCI)

Preclinical

1 6

Sevelamer hydrochloride

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease3 trials

A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Completed· Astellas logo

Astellas·Phase 2·NCT00505037·156 enrolled

A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Completed· Astellas logo

Astellas·Phase 3·NCT01057407·110 enrolled

Study of Phosphate Levels in Patients With Chronic Kidney Disease

Completed·VVifor Pharma·Phase 2·NCT00824460·154 enrolled

Peritoneal Dialysis2 trials

Sevelamer Hydrochloride in Peritoneal Dialysis Patients

Completed·TThe University of Hong Kong·N/A·NCT00745589·60 enrolled

Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis

Completed· Sanofi logo

Sanofi·Phase 3·NCT00196755·138 enrolled

LAM1 trial

Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing

Completed· Sanofi logo

Sanofi·Phase 2·NCT00324376·24 enrolled

End-Stage Renal Disease1 trial

Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease

Completed·TTel-Aviv Sourasky Medical Center·N/A·NCT01049815·175 enrolled

Dialysis1 trial

Dialysis Clinical Outcomes Revisited (DCOR) Trial

Completed· Sanofi logo

Sanofi·Phase 4·NCT00324571·2,000 enrolled

5 more indications

AIN1 trial

Head to Head Study Against Sevelamer Hydrochloride

Completed· Takeda logo

Takeda·Phase 3·NCT00441545·182 enrolled

Hyperphosphatemia1 trial

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Completed·KKissei Pharmaceutical Co., Ltd.·Phase 3·NCT01850602·213 enrolled

Safety and Efficacy1 trial

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride

Terminated·IIneos Healthcare Limited·Phase 3·NCT00844662·1,000 enrolled

Hemodialysis1 trial

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

Completed· Sanofi logo

Sanofi·Phase 3·NCT00268957·217 enrolled

Unspecified1 trial

Different Effects of Non-calcium Phosphate Binders on Serum Calcium

Completed·MMedical University of Lodz·Phase 4·NCT03451019·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Sevelamer hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sevelamer hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sevelamer hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Sanofi

Sevelamer hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease3 trials

Peritoneal Dialysis2 trials

LAM1 trial

End-Stage Renal Disease1 trial

Dialysis1 trial

AIN1 trial

Hyperphosphatemia1 trial

Safety and Efficacy1 trial

Hemodialysis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News